About Sherin Rouhani, MD, PhD
Dr. Rouhani is an inpatient oncologist at the Mass General Cancer Center. She earned her MD and PhD in immunology & cancer biology at the University of Virginia. Dr. Rouhani completed her internal medicine residency and hematology/oncology fellowship at the University of Chicago, and was a thoracic oncologist at the University of Chicago prior to joining the inpatient oncology team at MGH.
Dr. Rouhani’s clinical and research interest are in cancer immunotherapy and immunotherapy-related adverse events. She specializes in the care of patients who are hospitalized due to treatment side effects or complications from cancer.
Clinical Interests:
- Cancer Immunotherapy
- Immunotherapy toxicity
- Inpatient oncology
Treats:
- Adult
Locations
Mass General Cancer Center
55 Fruit St.
Boston, MA 02114
Phone: 617-726-5130
Phone: 877-726-5130
Mass General Cancer Center at Newton-Wellesley
2014 Washington St.
Newton, MA 02462
Phone: 617-219-1230
Medical Education
- MD, University Of Virginia
- Residency, University of Chicago Medical Center
- Fellowship, University of Chicago Medical Center
American Board Certifications
- Hematology, American Board of Internal Medicine
- Internal Medicine, American Board of Internal Medicine
- Medical Oncology, American Board of Internal Medicine
Accepted Insurance Plans
- Aetna
- Beech Street
- Blue Cross Blue Shield
- Blue Cross Blue Shield Medicare
- Cigna
- Commonwealth Care Alliance
- Coventry
- Fallon Health
- Harvard Pilgrim Health Care
- Humana
- Maine Community Health Options
- Mass General Brigham Health Plan
- MassHealth
- Medicaid ME
- Medicaid NH
- Medicaid RI
- Medicaid VT
- Medicare
- Medicare ACO
- Multiplan
- Railroad Medicare
- Senior Whole Health
- TriCare
- Tufts Health Plan
- Unicare
- United Health Care
- WellSense
- WellSense NH
Note: This provider may accept more insurance plans than shown; please call the practice to find out if your plan is accepted.
Research
Publications
-
Selected publications:
Rouhani SJ, Bestvina CM. Immunotherapy partners after progression: Right place, right time?. Cancer.2023 Jan 15;129(2):181-183. doi: 10.1002/cncr.34558.
Reschke R, Shapiro JW, Yu J, Rouhani SJ, Olson DJ, Zha Y, Gajewski TF. Checkpoint Blockade-Induced Dermatitis and Colitis Are Dominated by Tissue-Resident Memory T Cells and Th1/Tc1 Cytokines. Cancer Immunol Res. 2022 Oct 4;10(10):1167-1174. doi: 10.1158/2326-6066.
Mathias K, Rouhani S, Olson D, Bass AR, Gajewski TF, Reid P. Association Between Rheumatic Autoantibodies and Immune-Related Adverse Events. Oncologist. 2023 Jan 3;. doi: 10.1093/oncolo/oyac252.
Rouhani SJ, Yu J, Olson D, Zha Y, Pezeshk A, Cabanov A, Pyzer AR, Trujillo J, Derman BA, O'Donnell P, Jakubowiak A, Kindler HL, Bestvina C, Gajewski TF. Antibody and T cell responses to COVID-19 vaccination in patients receiving anticancer therapies. J Immunother Cancer. 2022 Jun;10(6). doi: 10.1136/jitc-2022-004766.
Strohbehn GW, Heiss BL, Rouhani SJ, Trujillo JA, Yu J, Kacew AJ, Higgs EF, Bloodworth JC, Cabanov A, Wright RC, Koziol AK, Weiss A, Danahey K, Karrison TG, Edens CC, Bauer Ventura I, Pettit NN, Patel BK, Pisano J, Strek ME, Gajewski TF, Ratain MJ, Reid PD. COVIDOSE: A Phase II Clinical Trial of Low-Dose Tocilizumab in the Treatment of Noncritical COVID-19 Pneumonia. Clin Pharmacol Ther. 2021 Mar;109(3):688-696. doi: 10.1002/cpt.2117.
Rouhani SJ, Eccles JD, Riccardi P, Peske JD, Tewalt EF, Cohen JN, Liblau R, M?kinen T, Engelhard VH. Roles of lymphatic endothelial cells expressing peripheral tissue antigens in CD4 T-cell tolerance induction. Nat Commun. 2015 Apr 10;6:6771. doi: 10.1038/ncomms7771.